Photomicrograph of a demyelinating MS-Lesion. Immunohistochemical staining for...
Photomicrograph of a demyelinating MS-Lesion. Immunohistochemical staining for CD68 highlights numerous macrophages (brown). Original Magnification 10x

Double danger

MS patients at a greater risk of cancer, new study suggests

New results of a 65-year follow-up study of nearly 7,000 Norwegian patients with Multiple Sclerosis (MS) suggest that patients may have a greater overall risk of developing cancer than the general population, with an especially high risk of cancer in respiratory organs, urinary organs and the central nervous system.

Presented at the 5th European Academy of Neurology (EAN) Congress in Oslo, Norway, the Norwegian study also indicated an increased risk of developing haematological cancers in non-MS siblings of MS patients, compared with both MS patients and the general population.

Cancer type

Cancer risk among MS patients compared to the non-MS population

Respiratory cancer

66% increase in risk

Central nervous system (CNS)

52% increase in risk

Urinary cancer

51% increase in risk

Overall cancer

14% increase in risk

Additional research could also identify the possible connections between haematological cancer and MS and new ways in which we could manage these conditions

Nina Grytten

This long-term analysis was based on patient records from 6,883 MS patients born between 1930–1979, who were registered with various Norwegian MS and Cancer Registries, and prevalence studies from Norway. The analysis also included data from 8,918 siblings without MS, and 37,919 non-MS individuals. “This study is the first to compare cancer risk in MS with non-affected siblings of MS patients. The risk assessment between these two groups is extremely interesting because they share the same genetics and environmental conditions,” noted Dr Nina Grytten, lead researcher of the study, from Haukeland University Hospital, Bergen, who presented the results at the EAN congress.

“Previous clinical studies of cancer risk in MS patients in various countries have shown inconsistent findings, so further research is needed to help improve our understanding in this area,” stated Dr Grytten. “This research outlines the need for greater awareness of cancer risk among MS patients, which should lead to shortened cancer diagnosis and more effective therapy in order to improve outcomes and survival.”

“Additional research could also identify the possible connections between haematological cancer and MS and new ways in which we could manage these conditions”, she added.

Recommended article

Multiple sclerosis is a lifelong disease that affects the central nervous system, especially the brain, spinal cord and optic nerves. It can lead to a wide range of symptoms, including problems with vision, arm or leg movement, sensation or balance. MS is one of the most common causes of disability in younger adults, and people with MS have on average 7 years shorter longevity.

Haematological cancer is a type of blood cancer that includes myeloma, lymphoma and leukaemia. There are many different types of haematological cancers, which can affect the blood, bone marrow and lymph nodes in the body. According to Dr. Grytten, the results of the investigation might suggest that MS and haematological cancer could share a common etiology, which can be important for future treatment of MS and prevention of both diseases.


Source: European Academy of Neurology (EAN)

28.06.2019

Read all latest stories

Related articles

Photo

Multiple sclerosis

Old cells repair damage in the brains of MS patients

A new study shows that there is a very limited regeneration of cells in the brain of patients diagnosed with multiple sclerosis (MS). These findings underline the importance of treating MS at an…

Photo

Childhood cancer

Molecular super-enhancers determine progression of neuroblastomas

Childhood neuroblastomas display extreme differences in the way they develop: they can shrink spontaneously or spread aggressively to healthy tissue. It is molecular super-enhancers that activate the…

Photo

Finding therapeutic targets

Pancreatic cancer: Seeking viable treatment strategies

Pancreatic cancer has the worst survival rate of any cancers, with immunotherapies currently offering negligible treatment benefits for patients. To help identify new therapeutic approaches,…

Related products

Beckman Coulter – Access Procalcitonin (PCT)

Immunoassays

Beckman Coulter – Access Procalcitonin (PCT)

Beckman Coulter, Inc.
Beckman Coulter – Prostate Health Index (phi)

Immunochemistry

Beckman Coulter – Prostate Health Index (phi)

Beckman Coulter, Inc.
DRG Instruments – DRG:Hybrid-XL

Immunochemistry

DRG Instruments – DRG:Hybrid-XL

DRG Instruments GmbH
FUJIFILM Wako - μTASWako i30

Immunoassays

FUJIFILM Wako - μTASWako i30

Wako Chemicals GmbH